Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$2.6B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. operates in the health care sector, specifically in biotechnology, focusing on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue

While revenue estimates are not available, any growth in revenue would signal increasing adoption of GRAIL's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. operates in the health care sector, specifically in biotechnology, focusing on early cancer detection through innovative blood tests. As the demand for advanced diagnostic tools grows, GRAIL's technology could play a crucial role in improving patient outcomes and reducing treatment costs.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In the last quarter, GRAIL reported an EPS of -$2.29, which was better than the expected -$3.00, marking a 23.67% surprise. However, the stock fell 2.26% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about GRAIL's upcoming earnings, given its consistent ability to beat EPS estimates in recent quarters. However, the lack of revenue guidance raises concerns about growth sustainability.

Bull Case

If GRAIL continues its trend of beating EPS expectations and shows signs of revenue growth, it could lead to a significant positive reaction from investors.

Bear Case

On the other hand, if GRAIL fails to meet expectations or provides no clear path to revenue growth, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given GRAIL's history of beating EPS estimates, this number will be closely watched to see if the trend continues.

Is there any indication of revenue growth or new product adoption?

Without revenue guidance, investors will be looking for any signs that GRAIL's products are gaining traction in the market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GRAIL's potential for revenue growth based on its recent product developments and market demand for early cancer detection.

Supporting Evidence

GRAIL has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing in a significant move, suggesting that traders expect a notable reaction based on the earnings report.

Key Risk

If GRAIL reports an EPS significantly better than -$2.29, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around GRAIL's ability to maintain its EPS beat trend while also demonstrating revenue growth.

Bull Confirmed If

A reported EPS better than -$2.29 along with any indication of revenue growth would confirm the bull case.

Bear Confirmed If

An EPS worse than -$2.29 without any revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±45.79%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats EPS expectations and provides positive revenue insights, history suggests the stock could rise by an average of +1.90% the following day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

Should GRAIL miss expectations, history suggests a potential decline of around -2.26% based on the average reaction following misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product adoption rates for GRAIL's cancer detection tests.
2Details on any partnerships or collaborations that may impact revenue.
3Management's outlook on future revenue growth and market expansion.
4Insights into operational efficiencies that could improve margins.
5Any commentary on competitive landscape and GRAIL's positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. operates in the health care sector, specifically in biotechnology, focusing on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue

While revenue estimates are not available, any growth in revenue would signal increasing adoption of GRAIL's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If GRAIL continues its trend of beating EPS expectations and shows signs of revenue growth, it could lead to a significant positive reaction from investors.

Bear Case

On the other hand, if GRAIL fails to meet expectations or provides no clear path to revenue growth, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given GRAIL's history of beating EPS estimates, this number will be closely watched to see if the trend continues.

Is there any indication of revenue growth or new product adoption?

Without revenue guidance, investors will be looking for any signs that GRAIL's products are gaining traction in the market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GRAIL's potential for revenue growth based on its recent product developments and market demand for early cancer detection.

Supporting Evidence

GRAIL has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing in a significant move, suggesting that traders expect a notable reaction based on the earnings report.

Key Risk

If GRAIL reports an EPS significantly better than -$2.29, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around GRAIL's ability to maintain its EPS beat trend while also demonstrating revenue growth.

Bull Confirmed If

A reported EPS better than -$2.29 along with any indication of revenue growth would confirm the bull case.

Bear Confirmed If

An EPS worse than -$2.29 without any revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±45.79%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats EPS expectations and provides positive revenue insights, history suggests the stock could rise by an average of +1.90% the following day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

Should GRAIL miss expectations, history suggests a potential decline of around -2.26% based on the average reaction following misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product adoption rates for GRAIL's cancer detection tests.
2Details on any partnerships or collaborations that may impact revenue.
3Management's outlook on future revenue growth and market expansion.
4Insights into operational efficiencies that could improve margins.
5Any commentary on competitive landscape and GRAIL's positioning.